Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBristol-Myers Squibb
About this trial
This study will explore how adults in Japan with pulmonary fibrosis decide whether to continue or discontinue antifibrotic therapy after experiencing antifibrotic therapy-related adverse events.
Eligibility criteria
Qualifiers
Pulmonary fibrosis (PF) participants in Japan. Note: This includes those clinically recognized as having idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF).
Participants who are ≥18 years of age at the time of providing informed consent via the web-based system.
Participants receiving outpatient care for pulmonary fibrosis (PF) who have been introduced to this study by a referring physician.
Participants who have a history of taking, or are currently taking, pirfenidone, nintedanib, or nerandomilast.
Disqualifiers
Participants currently participating in any interventional clinical trials (regardless of the study drug, excluding observational studies).
Participants who have undergone lung transplantation.
Discontinuation group only 1) Participants who discontinued AF therapy solely for reasons other than AE (e.g., financial reasons, disease progression).
Trial design
Treatments tested in this trial
- Antifibrotic therapy
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov